Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
36.70
+3.47 (10.44%)
At close: Apr 24, 2025, 4:00 PM
36.17
-0.53 (-1.44%)
Pre-market: Apr 25, 2025, 5:01 AM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
27.07B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
SMMT News
- 13 hours ago - Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 - Business Wire
- 1 day ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 1 day ago - Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China - Business Wire
- 10 days ago - Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition - Seeking Alpha
- 20 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics - Benzinga
- 5 weeks ago - Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer - Business Wire
- 2 months ago - Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs - PRNewsWire